- Previous Close
0.0014 - Open
0.0014 - Bid --
- Ask --
- Day's Range
0.0014 - 0.0014 - 52 Week Range
0.0002 - 0.0733 - Volume
47,809 - Avg. Volume
899 - Market Cap (intraday)
299 - Beta (5Y Monthly) 2.94
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.
www.regenerx.comPerformance Overview: RGRX
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RGRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RGRX
View MoreValuation Measures
Market Cap
299.00
Enterprise Value
1.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.00
Price/Book (mrq)
--
Enterprise Value/Revenue
18.15
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-148.50%
Return on Equity (ttm)
--
Revenue (ttm)
76.76k
Net Income Avi to Common (ttm)
-1.69M
Diluted EPS (ttm)
-0.9700
Balance Sheet and Cash Flow
Total Cash (mrq)
101.56k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-355.28k